cover image: The Making of a Pathogen Access

Premium 20.500.12592/1517799

The Making of a Pathogen Access

2024

What are advantages and disadvantages to having a narrower vs broader scope of pathogen samples and data to be shared under the PABS? [...] The speaker advocated for a narrower scope, emphasizing the importance of focusing on pathogens with known pandemic potential, such as coronaviruses and influenza, which is covered under the Pandemic Influenza Preparedness (PIP) framework. [...] What are the strengths and weaknesses of a centralized system? [...] The speaker emphasized the need for agreement on the definition of pathogens with pandemic potential and highlighted that Member States will have the opportunity to deliberate and select between a broader or narrower scope. [...] This determination would serve to delineate whether the pathogen falls within the purview of the proposed access and benefit sharing system.7 The Making of a PABS System: A Multi-Stakeholder Dialogue The PIP framework, which only applies to samples of influenza virus of pandemic potential, as a precedent for addressing other pathogens with pandemic potential was highlighted. [...] The urgency around sharing of organisms and data for pandemic pathogens would be diluted by increasing the complexity of the process and broadening to include pathogens that do not have known or likely pandemic potential. [...] Recommendation of the Council on Enhancing Access to and Sharing of Data. [...] The decision's ambition was to ensure fair and equitable benefit-sharing from DSI on genetic resources, and established a new mechanism via the establishment of a multilateral system and a global fund. [...] Acknowledging the necessity for flexibility in pandemic response frameworks to accommodate diverse epidemiological contexts and national capacities, the critical importance of rapid and unimpeded access to pathogens and genetic sequence data for effective pandemic response was highlighted. [...] The discussion concluded with reflections on the challenges of financing and incentivizing R&D, particularly in scenarios where only a fraction of projects reach the market.
Pages
17
Published in
Switzerland